# Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

> **NCT00140348** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cell Genesys** · enrollment: 80 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Immunotherapy allogeneic GM-CSF secreting cellular vaccine

## Key facts

- **NCT ID:** NCT00140348
- **Lead sponsor:** Cell Genesys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 80 (—)
- **Last updated:** 2007-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140348, "Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00140348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*